Selective Estrogen Receptor Modulators

@article{Haskell2003SelectiveER,
  title={Selective Estrogen Receptor Modulators},
  author={Sally G Haskell},
  journal={Southern Medical Journal},
  year={2003},
  volume={96},
  pages={469-476}
}
  • S. Haskell
  • Published 1 May 2003
  • Biology, Medicine
  • Southern Medical Journal
Because of recent concerns about the long-term risks of estrogen replacement therapy in postmenopausal women, there is growing interest in a group of compounds known as selective estrogen receptor modulators (SERMs). The SERMs bind to estrogen receptors and have tissue-specific effects that allow them to function as estrogen agonists in some tissues and estrogen antagonists in other tissues. There are four SERMs currently marketed in the United States. These include the triphenylethylenes… 
[Changes in the endometrium after tamoxifen therapy].
TLDR
Endometrial hyperplasia or endometrial carcinoma is identified histologically in only a few cases, while other findings related to tamoxifen therapy are stromal decidualisation, regressivehyperplasia, and foci of mucinous, clear cell and serous metaplasia.
Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens.
TLDR
The results suggest that the expression of ERalpha, ERbeta and GPR30 are influenced by sex steroids and might play a role in the response of cells to 17beta-estradiol and antiestrogens but are not the only factors involved in this process.
[Effects of tamoxifen on the expression of TGF-beta and p27 proteins in polyps and adjacent endometrium in postmenopausal women].
  • Sheldon Rodrigo BotogoskiS. Lima T. Aoki
  • Medicine, Biology
    Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia
  • 2009
TLDR
The TGF-beta expression is not related to the effect of tamoxifen on the growing of endometrial polyps, but the absence of polyps' malignization by tamoxIFen may be explained by the high expression of p27 protein in its glandular epithelium.
Acute tamoxifen treatment increases nitric oxide level but not total antioxidant capacity and adenosine deaminase activity in the plasma of rabbits.
TLDR
In conclusion, acute tamoxifen treatment may not affect the antioxidant status and cellular immunity, as evidenced by unaltered TAC and ADA, however, NO level was increased as early as 24 hours following tamoxIFen treatment.
Andrographolide prevents human breast cancer-induced osteoclastic bone loss via attenuated RANKL signaling
  • Z. ZhaiX. Qu K. Dai
  • Medicine, Biology
    Breast Cancer Research and Treatment
  • 2014
TLDR
Molecular analysis revealed that AP prevented osteoclast function by inhibiting RANKL-induced NF-κB and ERK signaling pathway in lower dose, as well as inducing apoptosis at higher dose (40 μM).
Efeitos do tamoxifeno sobre a expressão das proteínas TGF-β e p27 em pólipos e endométrio adjacente de mulheres após a menopausa
TLDR
The TGF-beta expression is not related to the effect of tamoxifen on the growing of endometrial polyps, but the absence of polyps' malignization by tamoxIFen may be explained by the high expression of p27 protein in its glandular epithelium.
Efficacy of tamoxifen and thymoquinone on tumor development, lipid peroxidation, and total antioxidant capacity in DMBA induced mammary carcinoma in female Sprague-Dawley rats
TLDR
In conclusion, both TAM and TQ appeared to prevent tumor induction by DMBA and ameliorated the adverse effect of TAM on lipid peroxidation but not body weight gain.
Controlled Ovarian Stimulation Protocols Alter Endometrial Histomorphology and Gene Expression Profiles
Although it is well appreciated that ovarian stimulation protocols for in vitro fertilization (IVF) alter endometrial receptivity, the precise cellular mechanisms are not known. To gain insights into
...
...

References

SHOWING 1-10 OF 98 REFERENCES
Selective estrogen receptor modulators: a look ahead.
TLDR
Raloxifene, used for prevention of postmenopausal osteoporosis and fragility fractures, also has favourable effects on bone mineral density, serum lipids and the incidence of invasive breast cancer in post menopausal women but does not stimulate the endometrium.
Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women.
TLDR
Droloxifene has estrogen agonistic properties regarding low densitylipoprotein and lipoprotein(a) metabolism, certain coagulation factors, and endothelium-dependent vasodilation but, unlike estrogen, has no effect on high density lipop protein/triglyceride metabolism and the fibrinolytic cascade.
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.
TLDR
Raloxifene favorably alters biochemical markers of cardiovascular risk by decreasing LDL-C, fibrinogen, and lipoprotein(a), and by increasing HDL2-C without raising triglycerides.
The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women.
TLDR
It is concluded that tamoxifen significantly reduces the levels of atherogenic lipids and fibrinogen in normal postmenopausal women, suggesting that the anti-estrogens may substantially reduce the risk of cardiovascular disease, which remains the most common cause of death among post menopausal women.
Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.
TLDR
The data suggest that the estrogen-progestin regimen increases breast cancer risk beyond that associated with estrogen alone, and were evident for the majority of invasive tumors with ductal histology and regardless of extent of invasive disease.
Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer.
TLDR
Positive evidence is provided that toremifene has antiatherogenic properties with potency to improve all lipoproteins that are associated with increased coronary heart disease (CHD) risk.
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer.
TLDR
In postmenopausal women, treatment with tamoxifen is associated with preservation of the bone mineral density of the lumbar spine, and whether this favorable effect on bone mineraldensity is accompanied by a decrease in the risk of fractures remains to be determined.
The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomised, controlled tamoxifen prevention study.
  • J. ChangT. Powles R. Singh
  • Medicine, Biology
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 1996
TLDR
The combination of tamoxifen and HRT results in a reduction of serum cholesterol, increase in BMD especially in the femur and appears not to have any adverse effect on coagulation factors.
...
...